CN Patent

CN108358899A — 人类组蛋白甲基转移酶ezh2抑制剂的盐形式

Assigned to Eisai R&D Management Co Ltd · Expires 2018-08-03 · 8y expired

What this patent protects

本发明提供了一种人类组蛋白甲基转移酶EZH2抑制剂的盐形式。本发明所提供的盐形式为N‑((4,6‑二甲基‑2‑氧代‑1,2‑二氢吡啶‑3‑基)甲基)‑5‑(乙基(四氢‑2H‑吡喃‑4‑基)氨基)‑4‑甲基‑4’‑(吗啉基甲基)‑[1,1’‑联苯基]‑3‑甲酰胺氢溴酸盐。本发明还提供了该化合物的特定晶型。

USPTO Abstract

本发明提供了一种人类组蛋白甲基转移酶EZH2抑制剂的盐形式。本发明所提供的盐形式为N‑((4,6‑二甲基‑2‑氧代‑1,2‑二氢吡啶‑3‑基)甲基)‑5‑(乙基(四氢‑2H‑吡喃‑4‑基)氨基)‑4‑甲基‑4’‑(吗啉基甲基)‑[1,1’‑联苯基]‑3‑甲酰胺氢溴酸盐。本发明还提供了该化合物的特定晶型。

Drugs covered by this patent

Patent Metadata

Patent number
CN108358899A
Jurisdiction
CN
Classification
—
Expires
2018-08-03
Drug substance claim
No
Drug product claim
No
Assignee
Eisai R&D Management Co Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.